Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Functional MR Measurements
研究概览
简要总结
The goal of this clinical research study is to learn if magnetic resonance imaging with magnetic resonance spectroscopy ("MRI/MRS" scanning) can measure any extra growth in the tumor that does not show up on regular MRI images. This study procedure will be performed on patients with recurrent glioblastoma who are either being treated with chemotherapy that blocks blood vessel growth, or will soon begin this type of chemotherapy.
详细描述
The Study Procedures:
MRI scanning is commonly used to check the status of glioblastoma. In this study, MRI scanning will also be used to try to better understand how chemotherapy that blocks blood vessel growth may be affecting the status of the glioblastoma.
The timing of all MRI scans for this study will be done on schedule for routine patient care. There will not be any extra MRI scans performed, but an MRS portion to the MRI scans will be added. The MRS results will be used in this study to look at the chemical differences between the cancerous and normal tissue, in order to try to better understand how your chemotherapy may be working.
Screening Tests:
Before you can begin this study, you will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests and procedures will be performed:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol
- •Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab.
- •Patients tumor must be located in an area that is amenable to the proposed imaging sequences.
- •Patients must be age 18 or older.
- •Karnofsky Performance Status Scale (KPS) >/=
- •Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial.
- •Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol.
排除标准
- •Patients with histologically proven intracranial glioblastoma or gliosarcoma will be eligible for this protocol
- •Patients with recurrent glioblastoma or gliosarcoma who are scheduled to start systemic chemotherapy with bevacizumab.
- •Patients tumor must be located in an area that is amenable to the proposed imaging sequences.
- •Patients must be age 18 or older.
- •Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial.
- •Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policies of the hospital.
结局指标
主要结局
Functional MR Measurements
时间窗: Baseline, Every 8 weeks and at Off Study
次要结局
未报告次要终点